VACCINE DEVELOPMENT FOR TUBERCULOSIS

结核病疫苗的开发

• 批准号: 7958684
• 负责人: ROBERT A SEDER
• 金额: $ 5.57万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958684
• 关键词: Adenovirus Vector; Aerosols; Animals; Bronchoscopes; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Health; Institution; Primates; Research; Research Personnel; Resources; Source; Subgroup; Tuberculosis; United States National Institutes of Health; Virulent; design; immunogenic; nonhuman primate; novel vaccines; vaccination strategy; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Tuberculosis (TB) remains a global health burden for which safe and novel vaccine strategies are needed. Studies using nonhuman primates are underway comparing BCG to prime/boost vaccination strategies using a prime of either BCG or a modified BCG designed to be more immunogenic, combined with a boost of an adenoviral vector delivered via aerosol. All animals have been immunized and a small subgroup has been challenged via bronchoscope with 500CFU of virulent TB (Erdman). The remaining animals will be challenged soon and the animals will be followed for 6 months post challenge.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 结核病（TB）仍然是全球健康负担，需要安全和新颖的疫苗策略。 正在进行使用非人灵长类动物的研究，比较卡介苗与初免/加强疫苗接种策略，使用卡介苗初免或旨在更具免疫原性的改良卡介苗，并结合通过气雾剂递送的腺病毒载体加强。 所有动物均已免疫，一小部分动物已通过支气管镜接受了 500CFU 的强毒结核病 (Erdman) 的攻击。 其余的动物将很快接受挑战，并且将在挑战后对这些动物进行 6 个月的跟踪。